.png){kind=icon}
.png){kind=icon}
Return
Pre-analytical Determinants of Patient Eligibility for Immune Checkpoint Inhibitors Revealed by Quantitative PD-L1 Analysis
.png){kind=icon}
OA
AI
A
L
C
L
M
S
S
V
A
P
A
M
F
DOI：10.1016/j.labinv.2026.106138.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The assessment of PD-L1 protein expression is a predictive biomarker for subsequent immune checkpoint inhibitor (ICI)-based therapies. The purpose of this study was to granularly and quantitatively define the impact of pre-analytical variables such as cold ischemia time and tissue block and slide aging on PD-L1 expression evaluation via immunohistochemistry.
Keywords:
false negative
immunohistochemistry
quality control
CD274
clinical trial
computational pathology
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.2
Papers:
5.4K
Citations:
1.1W
Organization
Cited Papers